WHO Drug Information Vol. 24, No. 4, 2010

Proposed INN: List 104 WHO Drug Information, Vol. 24, No. 4, 2010elsiglutidumelsiglutideelsiglutideelsiglutida[2-glycine(A>G),3-glutamic acid(D>E),8-serine(D>S),10-leucine(M>L),11-serine(N>S),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]human glucagon-like peptide 2 (GLP-2) fusion proteinwith hexalysinamideantidiarrhoeal[2-glycine(A>G),3-acide glutamique(D>E),8-sérine(D>S),10-leucine(M>L),11-sérine(N>S),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]peptide 2 semblable au glucagon humain (GLP-2)protéine de fusion avec l’hexalysinamideantidiarrhéique[2-glicina(A>G),3-acide glutámico(D>E), 8-serina(D>S),10-leucina(M>L),11-serina(N>S),16-alanina(N>A),24-alanina(N>A),28-alanina(Q>A)]péptido 2 similar al glucagón humano(GLP-2) proteínade fusión con hexalisinamidaantidiarréicoC 196 H 323 N 53 O 56 914009-84-0HGEGSFSSEL STILDALAAR DFIAWLIATK ITDKKKKKK 39Modified residue / Résidu modifié / Residuo modificadoK lysinamideempagliflozinumempagliflozinempagliflozineempagliflozina(1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitolantidiabetic(1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxan-3-yl]oxy]}phényl)méthyl]phényl}-D-glucitolantidiabétique(1S)-1,5-anhidro-1-C-{4-cloro-3-[(4-{[(3S)-oxan-3-il]oxi}fenil)metil]fenil}-D-glucitolhipoglucemianteC 23 H 27 ClO 7 864070-44-0HOOClHOHOOHOOH366